Gland Dysfunction News Today

Study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of Contact Lens Discomfort and signs of concomitant Meibomian Gland Dysfunction

/PRNewswire/ -- The "Meibomian Gland Dysfunction - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.coms offering. This report...

MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 Trials Bausch

-- Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials --TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-0...

Dry eye disease may not sound serious, but the results can be devastating. Some sufferers always feel like there is something stuck in their eyes.

Théa Pharmaceuticals has launched the Blepha EyeBag®; the newest addition to their bestselling Blepha eyelid care range (RRP: £19.99). The Blepha EyeBag® is a simple and effective treatment for a range of eye conditions including Meibomian Gland Dysfunction (MGD), Blepharitis, Stye, Chalazion and Dry Eye Disease ...

An alternative to laser protection glasses through the incorporation of gold nanoparticles within contact lenses has been developed.

The Dry Eye Syndrome Treatment Market To Witness Steadfast Growth

The automotive vertical to witness a technological awakening by Dry Eye Syndrome Treatment Market reaching US$ 5 Bn by 2030